Cetirizine hydrochloride was administered orally at 5 mg/cat, q24h, to 32 cats with allergic skin disease. Pruritus was reduced in 41% (13/32) of the cats. The antipruritic effect was repeatable and sustainable. There was no significant association between patient age, disease severity, or cutaneous reaction pattern and improvement during cetirizine administration. No adverse side effects were reported.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3239147 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Relationship between antihistamine residues in wastewater and airborne pollen concentrations: Insights into population-scale pollinosis response.
Sci Total Environ
January 2025
Swiss Federal Institute of Aquatic Science and Technology, Eawag, Dübendorf, Switzerland.
Pollinosis is the most prevalent allergic disorder. Assessing the impact of real-world pollen exposure on symptoms remains challenging due to extensive patient-level efforts required. This study explores the potential of wastewater-based epidemiology (WBE) to investigate the relationship between airborne pollen concentrations and antihistamine residues in wastewater as an indicator of pollinosis symptom treatment at the population-scale.
View Article and Find Full Text PDFDermatologic Adverse Events Following Afatinib in a Woman with Non-Small-Cell Lung Cancer: A Case Report.
Clin Cosmet Investig Dermatol
January 2025
Department of Dermatology and Venereology, Faculty of Medicine, Universitas Padjadjaran-Dr Hasan Sadikin Hospital, Bandung, West Java, Indonesia.
Epidermal growth factor receptor inhibitors (EGFRI) are biological factors used in several types of cancer, including non-small-cell lung cancers (NSCLC). One of the EGFR inhibitors that has been approved for NSCLC is afatinib. Dermatologic adverse events are the most commonly reported and may impair the patient's compliance to the therapy as it causes aesthetic discomfort and significantly impact the patient's quality of life.
View Article and Find Full Text PDFIntroduction: Recurrent priapism is a rare variant of ischemic priapism that involves recurrent erections typically lasting less than 4 h. The primary goal of treatment is to prevent future episodes, with options ranging from pharmacological treatments to various surgeries.
Case Presentation: A 38-year-old man experienced multiple episodes of priapism that were refractory to angioembolization of an arteriocavernous fistula and oral treatment with Cetirizine and Bicalutamide.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!